SCHEMBL14975641

SCHEMBL14975641

CCOC(=O)c1c(N)sc(C(N)=O)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 1.00
HPGD P15428 6/20 1.00
HSD17B10 Q99714 2/20 1.00
ALOX15 P16050 1/20 1.00
MAPK1 P28482 1/20 1.00
MAPT P10636 7/20 0.81
RAB9A P51151 4/20 0.81
NPC1 O15118 3/20 0.81
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
GAA P10253 4/20 0.70
KDM4E B2RXH2 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.66
LMNA P02545 1/20 0.63
TSHR P16473 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.60
FHIT P49789 1/20 0.60
NFKB1 P19838 2/20 0.59
NFKB2 Q00653 2/20 0.59
RELA Q04206 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1143421 0.90 MAPT (1.00) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL8198410 0.87 ALDH1A1 (1.00) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL9722730 0.85 MAPT (0.79) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL30216424 0.83 ALDH1A1 (0.71) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL7012743 0.83 ALDH1A1 (1.00) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL12082955 0.82 KDM4E (1.00) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL3498311 0.81 MAPT (0.77) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL1622309 0.81 FHIT (0.77) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL10508272 0.81 ALDH1A1 (0.79) ALDH1A1HPGDHSD17B10ALOX15MAPK1
SCHEMBL18671041 0.80 MAPT (0.84) ALDH1A1HPGDHSD17B10ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319056-A1 METHODS FOR TREATING CANCER UNIV INDIANA TRUSTEES (US) 2025-10-16 US disclosed
EP-4545535-A1 THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-04-30 EP disclosed
EP-4010344-B1 THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-10-02 EP disclosed
CN-114206884-B Thienopyrimidine derivatives as ACC inhibitors and use thereof 吉利德科学公司 2024-07-12 CN disclosed
WO-2024081714-A2 GroEL INHIBITORS FOR ANTIBIOTIC APPLICATIONS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-04-18 WO disclosed
EP-4010344-A1 THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2022-06-15 EP disclosed
US-11352371-B2 Thienopyrimidine derivatives as ACC inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2022-06-07 US disclosed
US-11352371-B2 Thienopyrimidine derivatives as ACC inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2022-06-07 US disclosed
CN-114206884-A Thienopyrimidine derivatives as ACC inhibitors and uses thereof 吉利德科学公司 2022-03-18 CN disclosed
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 US disclosed
EP-3048106-A1 THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2016-07-27 EP disclosed
EP-3048106-A1 THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2016-07-27 EP disclosed
EP-2782917-B1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER REC TECH LTD (GB) 2016-03-02 EP disclosed
EP-2782917-B1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER REC TECH LTD (GB) 2016-03-02 EP disclosed
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-10-30 US disclosed
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-10-30 US disclosed
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-10-30 US disclosed
EP-2782917-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2014-10-01 EP disclosed
WO-2013078126-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-05-30 WO disclosed
WO-2013078126-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352371-B2 Thienopyrimidine derivatives as ACC inhibitors and uses thereof ACACB, ACACA, ACAT2 ALDH1A1 103/4885HPGD 386/4885HSD17B10 156/4885
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKX, PRKCQ, PRKACA ALDH1A1 4002/4885HPGD 2297/4885HSD17B10 4648/4885
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C PRKCQ, PRKDC, PRKACA ALDH1A1 3832/4885HPGD 3241/4885HSD17B10 4266/4885
US-20250319056-A1 METHODS FOR TREATING CANCER HSP90AB1, HSP90B1, HSP90AB2P ALDH1A1 2316/4885HPGD 1425/4885HSD17B10 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.